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Abstract
Background: Beta-blockers reduce mortality among patients with systolic heart failure (HF), yet primary care provider
prescription rates remain low.
Objective: To examine the association between primary care physician characteristics and both self-reported and actual
prescription of beta-blockers among patients with systolic HF.
Design: Cross-sectional survey with supplementary retrospective chart review.
Participants: Primary care providers at three New York City Veterans Affairs medical centers.
Measurements: Main outcomes were: 1) self-reported prescribing of beta-blockers, and 2) actual prescribing of beta-
blockers among HF patients. Physician HF practice patterns and confidence levels, as well as socio-demographic and clinical
characteristics, were also assessed.
Results: Sixty-nine of 101 physicians (68%) completed the survey examining self-reported prescribing of beta-blockers.
Physicians who served as inpatient ward attendings self-reported significantly higher rates of beta-blocker prescribing
among their HF patients when compared with physicians who did not attend (78% vs. 58%; p=0.002), as did physicians
who were very confident in managing HF patients when compared with physicians who were not (82% vs. 68%; p=0.009).
Fifty-one of these 69 surveyed physicians (74%) were successfully matched to 287 HF patients for whom beta-blocker
prescribing data was available. Physicians with greater self-reported rates of prescribing beta-blockers were significantly
more likely to actually prescribe beta-blockers (p=0.02); however, no other physician characteristics were significantly
associated with actual prescribing of beta-blockers among HF patients.
Conclusions: Physician teaching responsibilities and confidence levels were associated with self-reported beta-blocker
prescribing among their HF patients. Educational efforts focused on improving confidence levels in HF care and increasing
exposure to teaching may improve beta-blocker presciption in HF patients managed in primary care.
Citation: Sinha S, Schwartz MD, Qin A, Ross JS (2009) Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician Predictors. PLoS
ONE 4(12): e8522. doi:10.1371/journal.pone.0008522
Editor: Pieter H. M. van Baal, Erasmus University Rotterdam, Netherlands
Received September 14, 2009; Accepted December 2, 2009; Published December 31, 2009
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: Funding source: New Researcher Seed Grant, Dept. of Veterans Affairs, Veterans Integrated Service Network 3 Award. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Sanjai.Sinha@med.va.gov
Introduction
Heart Failure (HF) was responsible for 3.3 million outpatient
visits and approximately 300,000 deaths in the United States in
2006, with annual health care costs exceeding $37 billion. [1] A
substantial body of randomized-controlled trial evidence has
demonstrated that beta-blockers reduce mortality in patients with
systolic HF. [2–5] Despite this trial evidence, and subsequent
consensus clinical practice guidelines [6], many of these patients
are not receiving beta-blockers [7,8] and proven therapy has only
slowly disseminated into practice. Understanding the gap between
guidelines and prescribing patterns is crucial to delivering better
care in this population.
Many factors may lead to underutilization of beta-blocker therapy
for HF patients. For instance, patient insurance coverage, income,
and medication co-payments impact the use of therapy [9,10],
although socioeconomic status was not associated with underutiliza-
tion of heart failure treatment. [11] Other patient factors may also be
associated with underutilization of beta-blocker therapy, such as
advanced age, asthma, COPD, and depression. [12–15]
The impact of physician characteristics on guideline-appropri-
ate care has been well studied for acute myocardial infarction
[16–19] and asthma [20,21], but has not been examined in the
context of HF care, with the exception of physician specialty
[8,22,23]. Physician demographics, including age [24] and years
since residency, along with teaching responsibilities and confi-
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Physician training and sex were not associated with reported
prescribing practice in asthmatics, but this has not been studied in
HF patients. [27] Self-reported barriers to HF care by generalists
(eg. confidence levels, co-management with cardiologists, fear of
adverse reactions) were not correlated with prescribing angiotensin
converting enzyme inhibitors (ACE-I) in HF, but may be related to
prescribing beta-blockers. [28–30]
In order to examine the effect of physician characteristics on
beta-blocker prescriptions, we used a cohort of heart failure
patients seen at one of three New York City VA medical centers
over a two-year period. Our aim was to examine the association
between physician characteristics and their confidence in HF
management, with self-reported and actual prescription of beta-
blockers among patients with HF being managed within a primary
care clinic.
Methods
Ethics Statement: Regarding the physician survey, all partici-
pants were required to sign written informed consent prior to
participating in the survey. This informed consent process was
reviewed and approved by both the JJP VA Medical Center
Institutional Review Board and the VA New York Harbor
Healthcare System Institutional Review Board. We do not require
a separate ethics statement.
We conducted a cross-sectional survey of primary care providers
at three New York City VA medical centers, with supplementary
retrospective chart review of a random sample of their HF
patients. Written informed consent was obtained by all providers
before their participation in the survey. The Institutional Review
Boards at both the James J. Peters VA Medical Center and the VA
New York Harbor Healthcare System (which includes both the
NY and Brooklyn medical centers) approved of this study. In the
United States, a physician assistant (PA) is a certified mid-level
medical provider licensed to practice medicine with the direct or
indirect supervision of a licensed doctor (an MD) or osteopathic
physician (a DO). A 2-year masters degree is required to obtain the
physician’s assistant title. Similarly, Nurse Practitioners hold
masters degrees and are licensed to practice with supervision. All
health care providers (Physicians, Nurse Practitioners, and
Physician Assistants) who were primary care providers for HF
patients were eligible for inclusion. Because nearly all (98%) of
these providers were physicians, we will refer to this group as
physicians throughout this article. All physicians identified at the
three medical centers were contacted via email and/or in person,
and those providing informed consent were enrolled.
The questionnaire measured physician age, sex, VA site,
specialty, and years since completing training. We asked
physicians to self-report their HF practice patterns, such as use
of beta-blockers and other medications for HF and confidence in
HF management and referral rates to cardiology (see Appendix S1
for full survey).
The two main outcomes were: 1) self-reported prescribing of
beta-blockers among HF patients, measured as the estimated
proportion of HF patients in their clinical practice being treated
with a beta-blocker; and 2) actual prescribing of beta-blockers
among HF patients, dichotomized as currently versus not currently
prescribed as documented in the progress note or pharmacy
record for the prior visit closest to the survey date. For actual
prescribing, we matched surveyed physicians to HF patients for
whom they were identified as the primary care provider.
Data for this sample of HF patients were collected for a study
that examined the association between beta-blocker use and
patient characteristics, the details of which have been previously
described. (12) Briefly, we trained two reviewers to use the VA’s
electronic medical record to abstract predefined patient informa-
tion for all patients of surveyed physicians with International
Classification of Disease, Ninth Revision (ICD-9) codes for systolic
HF (428.x) seen in the primary care clinic between August 2002
and August 2004. Any visit to the patient’s assigned primary care
physician, including those not coded for HF, was counted toward
inclusion in our sample. We excluded patients without a
documented systolic ejection fraction (EF) less than or equal to
45% or who had fewer than 3 visits over the study period. Beta-
blocker use in heart failure patients was a VA performance
measure at the time of this study, but no electronic reminder was
used to prompt prescribing.
For self-reported prescribing of beta-blockers among HF
patients, we used non-parametric Spearman Correlation and
Wilcoxon Rank-Sum tests to examine the independent effects of
physician characteristics, including demographics, self-reported
practice patterns, and confidence in HF management, on self-
reported prescribing. For actual prescribing of beta-blockers
among HF patients, we used Generalized Estimation Equation
modeling to examine the independent effects of physician
characteristics on actual prescribing, adjusting for patient
characteristics our work had previously shown to be associated
with beta-blocker use: patient age, ejection fraction, and past
medical history of chronic obstructive lung disease, asthma, and
depression. These analyses also accounted for the clustering (non-
independence) of patients among primary care providers. All
statistical tests were two-tailed, using a type I error rate of 0.05,
and were performed using SAS 9.1 (SAS Institute, Inc., Cary,
NC).
Results
Sixty-nine of 101 physicians (68%) identified as practicing in the
primary care clinics at one of the three VA medical centers
completed the survey. Mean age was 45 years, 51% were female,
90% had a medical degree, and 81% had received clinical post-
graduate training in primary care fields: family medicine or
internal medicine without sub-specialty training, with the
exception of geriatrics (Table 1). Nearly half (46%) were
responsible for outpatient precepting (ie. Teaching) of post-
graduate trainees at least once a week and 71% served as teaching
attendings (ie. Supervising physician) on the inpatient hospital
wards at least one month per year. On average, physicians
reported that 23% of their patients had been diagnosed with HF;
30% were very confident in management of HF patients and 49%
reported not often consulting cardiologists for management input
for these patients. Mean self-reported prescribing rates among HF
patients was 72% for beta-blockers, 84% for ACE-inhibitors, and
79% for diuretics.
Physician Characteristics and Self-Reported Prescribing of
Beta-Blockers
Few physician clinical and demographic characteristics were
significantly associated with self-reported prescribing of beta-
blockers among HF patients, although significant associations for
several other measures of confidence and experience in managing
HF patients were observed (Table 2). Physicians whose teaching
responsibilities included serving as attendings on the inpatient
wards at least one month per year self-reported significantly higher
rates of beta-blocker prescribing among their HF patients when
compared with physicians who did not attend as often (78% vs.
58%; p=0.002). In addition, we observed two associations that
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teaching responsibilities included outpatient precepting at least
once per week self-reported higher rates of beta-blocker prescrib-
ing when compared to physicians who did not precept as often
(79% vs. 69%; p=0.09) and physicians who had received a
medical degree self-reported higher rates of beta-blocker prescrib-
ing when compared with physicians who had received a degree of
osteopathy and nurses (74% vs. 54%; p=0.07). There were no
significant differences in self-reported rates of beta-blocker
prescribing among HF patients for other physician clinical and
demographic characteristics, including age, sex, clinical post-
graduate training, years since post-graduate training, and site of
clinical practice.
Physicians who were very confident in managing HF patients
self-reported higher rates of beta-blocker prescribing among their
HF patients when compared with physicians who were not (82%
vs. 68%; p=0.009). In addition, physicians who self-reported
prescribing ACE-Inhibitors and diuretics among 90% or more of
their HF patients self-reported higher rates of beta-blocker
prescribing when compared with physicians who self-reported
rates below 90% (ACE-Inhibitors: 80% vs. 61%; p,0.001;
Diuretics: 77% vs. 67%; 0.005). Finally, we observed non-
significant, but potentially important, associations in our two
other measures of physician confidence and experience in
managing HF patients, as physicians that estimated that 20% or
more of their patients have been diagnosed with HF and
physicians who consulted cardiologists least frequently for HF
management self-reported higher rates of beta-blocker prescribing
(p-values=0.07).
Physician Characteristics and Actual Prescribing of
Beta-Blockers
Among 69 surveyed physicians, 51 (74%) were successfully
matched to 287 of the 368 (78%) HF patients we had previously
studied when examining associations between patient character-
istics and beta-blocker use among HF patients.(12) Each physician
was matched to an average of 5.6 patients (interquartile range: 2–
8) for this analysis.
Of these 287 patients, 237 (83%) were currently prescribed a
beta-blocker. There were no significant differences between
physicians who were and who were not successfully matched to
patients with respect to self-reported beta-blocker prescribing or
any other clinical or demographic characteristic or measure of
confidence or experience in managing HF patients with the
exception of frequency of cardiology consultation, as 57% of
physicians that were successfully matched to patients reported
consulting cardiology not very often as opposed to 28% of
physicians that were not matched (p=0.03).
Few physician characteristics were significantly associated with
actual prescribing of beta-blockers among HF patients (Table 3).
Actual prescribing of beta-blockers was not significantly associated
with physician age, clinical education, years since post-graduate
training, practice site, or whether their teaching responsibilities
included precepting in the outpatient clinics at least once per week
or attending on the inpatient wards at least one month per year (p
values.0.15), although there was a non-significant trend observed
of female and non-primary care trained physicians being less likely
to actually prescribe beta-blockers among their HF patients
(p=0.06 and p=0.07, respectively). Similarly, actual prescribing
of beta-blockers was not signficantly associated with physicians’
estimated proportions of patients diagnosed with HF, frequency of
cardiology consultation, or confidence in managing HF patients (p
values.0.25). However, physicians with greater self-reported rates
of prescribing beta-blockers among their HF patients were
significantly more likely to actually prescribe beta-blockers to
their HF patients (p=0.02); a similar, non-significant relationship
was observed for self-reported ACE-Inhibitor prescribing and
actual beta-blocker prescribing (p=0.07), but not for diuretic
prescribing (p=0.34).
Discussion
Improving physician guideline adherence in HF care is an
important performance measure within the VA health care system
as well as nationally. Our current research focused on identifying
physician characteristics as predictors of both self-reported and
actual beta-blocker prescription. We found that primary care
physicians reported high rates of beta blocker prescribing (72%) in
their HF patients and had even higher rates of actual prescription
(83%). Although a number of individual physician characteristics
were associated with greater self-reported rates of beta-blocker
Table 1. Physician Characteristics (n=69).
Characteristic No. (%)
*
Mean age, y (IQ range) 45 (36–53)
Sex
Female 35 (51)
Male 34 (49)
Clinical education
Medical degree 62 (90)
Doctor of osteopathy or nursing degree 7 (10)
Clinical post-graduate training
{
Primary Care 51 (81)
Other Internal Medicine Subspecialty 12 (19)
Mean time since post-graduate training, y (IQ range) 13 (5–20)
Clinical practice site
Bronx 31 (45)
Brooklyn 17 (25)
Manhattan 21 (30)
Teaching responsibilities include
Outpatient precepting$once per week 32 (46)
Inpatient wards $ one month per year 49 (71)
Mean estimated percentage of patients with HF, % (IQ range) 23 (10–30)
Frequency of consultation with a cardiologist when managing
HF patients
Not very often 34 (49)
Somewhat, moderately, or very often 35 (51)
Confidence in management of HF patients
Not very, somewhat, or moderately 48 (70)
Very 21 (30)
Mean self-reported rates of prescribing among HF patients, %
(IQ range)
Beta-blockers 72 (60–90)
ACE-inhibitors 84 (80–95)
Diuretics 79 (70–95)
Note: IQ=Interquartile; HF=Heart Failure; ACE=Angiotensin-Converting
Enzyme.
*Values expressed as number (percentage) unless otherwise noted. Percentages
may not sum to 100 because of rounding.
{Among physicians with a medical degree or doctorate of osteopathy.
doi:10.1371/journal.pone.0008522.t001
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associated with greater actual rates of prescribing. The only
characteristic that was associated with greater actual prescribing
rates was greater self-reported prescribing rates. We cannot be
certain that self-reported prescribing is reflecting physician’s self-
perception of their practice patterns or ideal practice, but the
similar rates of self-reported and actual prescribing suggest it
represents self-perception. Self-reported prescribing remains an
interesting outcome to study for two reasons. First, it is a measure
of physicians’ understanding of their own prescribing behavior.
Table 2. Self-reported prescribing of beta-blockers among heart failure patients, stratified by physician characteristics (n=69).
Physician Characteristics Self-reported Rates, Mean (95% Confidence Interval) P value
Age, y 0.21
30–39 78 (73–84)
40–49 73 (64–82)
50+ 64 (51–77)
Sex 0.15
Female 75 (68–82)
Male 69 (61–76)
Clinical education 0.07
Medical degree 74 (69–79)
Doctor of osteopathy or nursing degree 54 (25–82)
Clinical post-graduate training* 0.76
Primary Care 74 (68–79)
Other Internal Medicine Subspecialty 73 (61–85)
Years since post-graduate training 0.35
10 or less 74 (67–81)
Greater than 10 69 (62–78)
Clinical practice site 0.49
Bronx 71 (64–78)
Brooklyn 70 (55–83)
Manhattan 76 (67–85)
Teaching responsibilities include
Outpatient precepting $1 per week 0.09
No 69 (59–75)
Yes 79 (73–83)
Inpatient wards $1 month per year 0.002
No 58 (46–70)
Yes 78 (73–82)
Estimated percentage of patients with HF 0.07
Less than 20% 67 (58–75)
20% or more 78 (72–83)
Frequency of cardiology consultation when managing HF patients 0.07
Not very often 77 (71–83)
Somewhat, moderately, or very often 67 (59–75)
Confidence in management of HF patients 0.009
Not very, somewhat, or moderately 68 (61–74)
Very 82 (76–88)
Self-reported rates of prescribing ACE-inhibitors among HF patients ,0.001
Less than 90% 61 (52–70)
90% or more 80 (75–85)
Self-reported rates of prescribing diuretics among HF patients 0.005
Less than 90% 67 (60–74)
90% or more 77 (70–84)
Note: HF=Heart Failure; ACE=Angiotensin-Converting Enzyme.
*Among physicians with a medical degree or doctorate of osteopathy.
doi:10.1371/journal.pone.0008522.t002
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conveying some amount of information of how physicians practice
‘‘in general’’, as opposed to for each individual case.
Understanding which physician characteristics are associated
with greater self-reported prescribing of beta-blockers for patients
with HF can inform future efforts to improve care. We found that
physicians who were more confident in their own skills at
managing patients with HF had higher self-reported prescribing
rates, suggesting that interventions to increase confidence, such as
education programs, may lead to improved care. This finding was
additionally reflected by a non-significant trend we observed of
greater self-reported prescribing rates among physicians who
consulted specialists less often for HF care. Similarly, we found
that physicians with teaching responsibilities also had higher self-
reported prescribing rates, reinforcing the common wisdom that to
teach is to learn. Our findings are also consistent with prior
research that has shown increased confidence is associated with
greater self-reported prescribing rates of ACEIs among heart
failure patients. [30] Quality improvement programs should
consider focusing on increasing confidence in HF management
amongst primary care physicians, perhaps through CME activi-
ties, lecture series, journal clubs, or other HF- based learning
modules on a regular basis.
We had a unique opportunity to explore actual beta-blocker
prescribing rates within a sub-sample of our physicians to test
whether the same characteristics that were associated with self-
reported prescribing rates were also associated with actual
prescribing rates. None of the characteristics we examined,
Table 3. Regression estimates from independent Generalized Estimation Equation models examining the association between
each physician characteristic and actual prescribing of beta-blockers (mean=83%) among heart failure patients (n=51 physicians
and their 287 patients).*
Physician Characteristic Odds Ratio 95% Confidence Interval P value
Age 0.98 0.95, 1.01 0.25
Sex
Male ref ref
Female 0.50 0.25, 1.02 0.06
Clinical education
Medical degree ref ref
Doctor of osteopathy or nursing degree 2.39 0.60, 9.55 0.22
Clinical post-graduate training
{
Primary Care ref ref
Other Internal Medicine Subspecialty 0.43 0.17, 1.08 0.07
Years since post-graduate training 0.97 0.94, 1.01 0.20
Clinical practice site
Bronx ref ref
Brooklyn 1.53 0.68, 3.45 0.31
Manhattan 1.45 0.63, 3.38 0.38
Precepts in outpatient setting $1p e rw e e k
Yes ref ref
No 0.61 0.30, 1.24 0.17
Inpatient wards $1 month per year
Yes ref ref
No 1.07 0.39, 2.92 0.89
Estimated percentage of patients with HF 0.99 0.97, 1.01 0.38
Frequency of cardiology consultation when managing HF patients
Not very often ref ref
Somewhat, moderately, or very often 0.99 0.49, 2.00 0.97
Confidence in management of HF patients
Not very, somewhat, or moderately 0.69 0.36, 1.34 0.28
Very ref ref
Among HF patients, self-reported rates of prescribing
Beta-blockers 1.02 1.00, 1.04 0.02
ACE-inhibitors 1.03 1.00, 1.05 0.07
Diuretics 1.01 0.99, 1.02 0.34
Note: HF=Heart Failure; ACE=Angiotensin-Converting Enzyme.
*Generalized Estimation Equation models were additionally adjusted for patient age, ejection fraction, and past medical history of chronic obstructive lung disease,
asthma, and depression.
{Among physicians with a medical degree or doctorate of osteopathy.
doi:10.1371/journal.pone.0008522.t003
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scribing such as confidence and teaching responsibilities, were
associated with actual prescribing rates, with the exception of self-
reported rates. These findings are somewhat perplexing but our
study was limited by a small sample size and possibly did not have
the power to detect true differences in actual prescribing rates
between physician subgroups. However, our analyses are explor-
atory and inform future research.
There are other considerations in interpreting our results. First,
we only examined beta-blocker prescribing for patients with HF
and did not address the impact of physician characteristics on
other important dimensions of HF care quality, such as use of
other recommended medications or non-pharmacological treat-
ments, patient experiences and satisfaction with care, or patient
outcomes. Second, we examined self-reported and actual pre-
scribing rates, but were unable to examine actual patient
adherence to prescribed medications. Physician characteristics
may also be associated with patient adherence to prescribed
therapy. Finally, our study was limited to physicians and patients
at three New York City-based VA medical centers and may not be
generalizable to the general population. Importantly, all VA
medical centers use an integrated electronic medical record system
that includes physician reminders to prompt use of recommended
preventive and chronic disease care, although no prompts address
beta-blocker prescription among outpatients with HF. Neverthe-
less, rates of beta-blocker prescribing may be higher than in the
general population.
Our findings suggest that some physician clinical characteristics
such as teaching responsibilities and confidence levels, are
associated with self-reported beta-blocker prescribing in HF
patients. Targeting these characteristics by improving education
of primary physicians, and increasing their exposure to teaching
may improve beta-blocker presciption in HF patients followed in
primary care settings.
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